The European Medicines Agency has emerged as the second major regulatory venue shaping the global peptide therapeutics landscape, often setting precedents the FDA later mirrors. The EMA approved semaglutide as the first GLP-1 receptor agonist with a formal cardiovascular and stroke benefit indication (March 27, 2026), and granted a CHMP positive opinion for the Wegovy pill (oral semaglutide 25 mg) on May 22, 2026, paving the way for EU launches in H2 2026 carrying the SELECT MACE-reduction labeling. Oncopeptides submitted a Type II variation on June 12, 2026 to move the Pepaxti (melflufen) peptide-drug conjugate into third-line multiple myeloma, and the CHMP adopted a positive opinion on September 17, 2026. Pepaxti remains authorized in the EU, although the FDA withdrew its U.S. approval on February 23, 2024.
The agency's first-ever dedicated 'Guideline on the Development and Manufacture of Synthetic Peptides' (EMA/CHMP/CVMP/QWP/367182/2025) became legally effective June 1, 2026, covering manufacturing routes, peptide-specific impurity types, pooling strategy in preparative chromatography, comparability requirements, and analytical control for both human and veterinary synthetic peptide APIs. Biological peptides produced by recombinant technology and radiopharmaceuticals fall outside the scope. The standard arrives on the same regulatory calendar as the FDA's July 23-24 PCAC peptide reclassification review and the May 2026 EU CHMP Wegovy pill opinion.
Stories here cover CHMP scientific opinions, EU marketing authorizations, EMA pharmacovigilance signals, and the diverging or converging US-EU regulatory paths for peptide therapeutics. See #wegovy, #semaglutide, regulatory news, and #manufacturing for adjacent threads.
Oncopeptides announced on Thursday, September 17, 2026 that the European Medicines Agency's CHMP adopted a positive opinion to extend the indication of Pepaxti (melflufen), given with dexamethasone, to adults with multiple myeloma who have had at least two prior lines of therapy and whose disease is refractory to lenalidomide and to the last line of therapy. Pepaxti's current EU label covers fourth-line and later patients whose disease is triple-class refractory, so the change would drop that requirement; the opinion rests on the Phase 3 OCEAN trial, and the European Commission is expected to decide within 30 to 60 days. Oncopeptides CEO Sofia Heigis said the broader label 'effectively doubles' the company's addressable patient population. The FDA withdrew the U.S. approval of the same drug, sold there as Pepaxto, on February 23, 2024, after concluding that the OCEAN confirmatory trial did not confirm its clinical benefit.
The U.S. Food and Drug Administration confirmed via press announcement Friday September 4, 2026 that it will convene a joint workshop with the European Medicines Agency (EMA) on Friday September 25, 2026 to discuss regulatory considerations for herbal medicinal and botanical drug products intended for medicinal use. The workshop follows the FDA's ongoing public-input process on botanical drug development that generated substantial biotech and pharmaceutical industry commentary earlier in 2026. Botanical drugs occupy an underdeveloped regulatory category in the U.S. — FDA has approved only two botanical drugs to date (Veregen sinecatechins from green tea for genital warts, approved 2006; Fulyzaq crofelemer from Croton lechleri sap for HIV-related diarrhea, approved 2012). Proposed legislation in the U.S. would extend 12-year market exclusivity to FDA-approved botanical drugs, matching the biologics exclusivity framework. The Sept 25 workshop matters for the peptide-industry pipeline because plant-derived and marine-organism-derived peptide products (defensins, ranatuerin analogs, plant-defensin-based antimicrobials) occupy a similar regulatory gray zone between conventional pharmaceuticals and dietary supplements.
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) closed its July 20-23, 2026 meeting with a recommendation for EU marketing authorisation of Lyrokaul (lerodalcibep). Lerodalcibep is a third-generation PCSK9 inhibitor administered as a once-monthly self-administered subcutaneous injection. The active substance is an adnectin-Fc fusion protein that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), preventing PCSK9-mediated degradation of LDL receptors in the liver and enhancing LDL-C clearance from circulation. In the Phase 3 LIBerate-HeFH registrational trial, adults with heterozygous familial hypercholesterolaemia (HeFH) on maximally tolerated statin therapy achieved placebo-adjusted LDL-C reductions of roughly 59-65% by Week 24, with approximately two-thirds of participants reaching European Society of Cardiology-recommended targets. The CHMP recommendation covers use in addition to diet, alone or in combination with other lipid-lowering therapies. European Commission marketing authorisation decisions typically follow CHMP recommendations by 2-3 months. Lerodalcibep received US FDA approval earlier in 2026 under the brand name Lerochol. The EU authorization would add a third-generation PCSK9 modality alongside injectable antibodies (Repatha/evolocumab, Praluent/alirocumab), the siRNA (Leqvio/inclisiran), and the oral macrocyclic peptide (LIPFENDRA/enlicitide, US-only as of July 25, 2026).
The European Medicines Agency's first-ever dedicated 'Guideline on the Development and Manufacture of Synthetic Peptides' (EMA/CHMP/CVMP/QWP/367182/2025) entered into force June 1, 2026 after adoption by CHMP on December 1, 2025 and CVMP on December 4, 2025. The guideline applies to both new and existing synthetic peptide active substances used in human and veterinary medicines, including investigational medicinal products and post-authorisation changes, and covers manufacturing routes, peptide-specific impurity types, pooling strategy in preparative chromatography, comparability requirements, characterization, specifications, and analytical control. Biological peptides produced by recombinant technology and radiopharmaceuticals are excluded. The standard arrives on the same regulatory calendar as the FDA's PCAC peptide reclassification review (July 23-24, 2026) and the FDA's 503B GLP-1 bulks exclusion comment window (closes June 29).
Oncopeptides announced on Monday, May 11, 2026 that it intends to submit a Type II variation application to the European Medicines Agency to extend the Pepaxti (melflufen) label to third-line multiple myeloma, with first regulatory feedback expected before the end of 2026 and a European Commission decision in the first half of 2027. Pepaxti, a peptide-drug conjugate given with dexamethasone, is authorized in the EU for adults who have had at least three prior lines of therapy and whose disease is refractory to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. The company said a third-line label would double Pepaxti's addressable patient population in Europe. The drug is not available in the U.S.: the FDA withdrew its approval, under the name Pepaxto, on February 23, 2024.
The European Medicines Agency formally approved semaglutide with cardiovascular and stroke-related benefits — a first for any GLP-1 receptor agonist in Europe.